Evidence map›Paper›PMID 23645635›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.

Imran Rizvi, Umut A Gurkan, Savas Tasoglu, Nermina Alagic, Jonathan P Celli, Lawrence B Mensah, Zhiming Mai, Utkan Demirci, Tayyaba Hasan

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02824471 (Sickle Cell Disease), which is not on this map. Cited by 138 papers.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02824471 recruitingnot on this mapstarted 2014, after this paper: background citation

Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease

TypeobservationalSponsorUniversity Hospitals Cleveland Medical CenterRan2014 to 2028Enrolled100ConditionsSickle Cell DiseaseArmsSCD Group
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 236 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Imran RizviWellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Umut A Gurkan
Savas Tasoglu
Nermina Alagic
Jonathan P Celli
Lawrence B Mensah
Zhiming Mai
Utkan Demirci
Tayyaba Hasan
Harvard University · USBrigham and Women's Hospital · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USUniversity of Massachusetts Boston · US

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tayyaba Hasan · 2001 to 2026
$27.9M
Point-of-Care Rapid Blood Testing Using Microfluidic DevicesR01AI081534 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2009 to 2013
$2.1M
Heterocellular 3D ovarian tumor arrays for imaging and mechanistic combinationsR01CA158415 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2012 to 2016
$2.0M
Ovarian Cancer PDT: Multi-intracellular targeting and Image-guided dosimetryR01CA160998 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2011 to 2015
$2.0M
Minimizing the role of cryoprotectant toxicity for cryopreservationR01EB015776 · NIBIB · STANFORD UNIVERSITY · PI DEMIRCI, UTKAN · 2012 to 2015
$1.5M
Antibody-based cell purification at resource limited setting for HIVR21AI087107 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI DEMIRCI, UTKAN · 2010 to 2011
$488k
Nano-Acoustic Masonry of Microgels for Bottom-Up Tissue EngineeringR21HL112114 · NHLBI · PENNSYLVANIA STATE UNIVERSITY, THE · PI DEMIRCI, UTKAN, DEMIREL, MELIK · 2012 to 2013
$452k
Mechanism-based therapies for pancreatic cancer informed by stromal microrheologyK99CA155045 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CELLI, JONATHAN P · 2011 to 2012
$324k
NCI NIH HHS 5P01CA084203NCI NIH HHS K99 CA155045NCI NIH HHS K99CA155045NCI NIH HHS P01 CA084203NCI NIH HHS R01 CA158415NCI NIH HHS R01CA158415NCI NIH HHS R01 CA160998NCI NIH HHS R01CA160998NHLBI NIH HHS R21 HL112114NHLBI NIH HHS R21-HL112114NIAID NIH HHS R01 AI081534NIAID NIH HHS R01AI081534NIAID NIH HHS R21 AI087107NIAID NIH HHS R21-AI087107NIBIB NIH HHS R01 EB015776NIBIB NIH HHS R01EB015776
6 · The paper itself

Abstract

Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage disease that is extensively disseminated intraperitoneally and prognosticates the poorest outcomes. Primarily metastatic within the abdominal cavity, ovarian carcinomas initially spread to adjacent organs by direct extension and then disseminate via the transcoelomic route to distant sites. Natural fluidic streams of malignant ascites triggered by physiological factors, including gravity and negative subdiaphragmatic pressure, carry metastatic cells throughout the peritoneum. We investigated the role of fluidic forces as modulators of metastatic cancer biology in a customizable microfluidic platform using 3D ovarian cancer nodules. Changes in the morphological, genetic, and protein profiles of biomarkers associated with aggressive disease were evaluated in the 3D cultures grown under controlled and continuous laminar flow. A modulation of biomarker expression and tumor morphology consistent with increased epithelial-mesenchymal transition, a critical step in metastatic progression and an indicator of aggressive disease, is observed because of hydrodynamic forces. The increase in epithelial-mesenchymal transition is driven in part by a posttranslational up-regulation of epidermal growth factor receptor (EGFR) expression and activation, which is associated with the worst prognosis in ovarian cancer. A flow-induced, transcriptionally regulated decrease in E-cadherin protein expression and a simultaneous increase in vimentin is observed, indicating increased metastatic potential. These findings demonstrate that fluidic streams induce a motile and aggressive tumor phenotype. The microfluidic platform developed here potentially provides a flow-informed framework complementary to conventional mechanism-based therapeutic strategies, with broad applicability to other lethal malignancies.

Indexed as

Models, BiologicalAscitesBiomarkers, TumorCadherinsCell Culture TechniquesEpithelial-Mesenchymal TransitionErbB ReceptorsFemaleGene Expression Regulation, NeoplasticHumansMicrofluidic Analytical TechniquesNeoplasms, Glandular and EpithelialOvarian NeoplasmsPeritoneal NeoplasmsBiomarkers, TumorCadherinsErbB Receptorscombination therapiesmolecular targetsphotodynamic therapystress responsetumor microenvironment

Identifiers

PMID23645635
PMCPMC3670329
OpenAlexW2069579706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.